Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chicago, Illinois 60611


Purpose:

The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also examines what effect other drugs have on how the body handles 141W94.


Criteria:

Inclusion Criteria Patients must have: - Documented HIV infection. - HIV RNA >= 400 copies/ml within 14 days prior to randomized study drug administration. - No active AIDS-defining opportunistic infection or disease. - Signed, informed consent from parent or legal guardian of patients less than 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Unlikely to complete the randomized dosing period. - Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with drug absorption or ability to take oral medications. - Serious medical conditions (e.g., diabetes, cardiac dysfunction, hepatitis) that would compromise patient safety. Concurrent Medication: Excluded: - Cytotoxic chemotherapeutic agents (except local treatment for Kaposi's sarcoma). - Investigational treatments (treatment through Treatment IND or expanded-access programs are evaluated individually). - Immunomodulating agents such as systemic, high-dose corticosteroids, interleukins, or interferons. - Terfenadine, astemizole, cisapride, triazolam, midazolam, and ergotamine/dihydroergotamine-containing regimens. Concurrent Treatment: Excluded: Radiation therapy (except local treatment for Kaposi's sarcoma). Patients with the following prior conditions are excluded: Clinically relevant pancreatitis or hepatitis within the last 6 months. Prior Medication: Excluded: - Cytotoxic chemotherapeutic agents within 30 days of study drug administration (except local treatment for Kaposi's sarcoma). - Protease inhibitor therapy. - Dose of vaccine through an investigational HIV vaccine trial within the 3 months prior to study drug administration. - Immunomodulating agents such as systemic, high-dose corticosteroids, interleukins, or interferons within 30 days of study drug administration. Prior Treatment: Excluded: Radiation therapy within 30 days prior to study drug administration (except local treatment for Kaposi's sarcoma). Risk Behavior: Excluded: Current alcohol or illicit drug use that may interfere with drug absorption or ability to take oral medication. Required: NRTI therapy at day of entry and up to screening. Required: >= 12 weeks of NRTI therapy.


Study is Available At:


Original ID:

264E


NCT ID:

NCT00002202


Secondary ID:

PROA/B3006


Study Acronym:


Brief Title:

A Comparison of 141W94 and Indinavir in HIV-Infected Patients


Official Title:

A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 With Indinavir in Combination With Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy, in NRTI-Experienced, Protease Inhibitor (PI)-Naive, HIV-1-Infected Patients.


Overall Status:

Completed


Study Phase:

Phase 3


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

NIH AIDS Clinical Trials Information Service


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Endpoint Classification: Pharmacokinetics Study,


Number of Arms:

0


Number of Groups:

0


Total Enrollment:

460


Enrollment Type:


Study Dates

Verification Date:November 1998
Last Changed Date:June 23, 2005
First Received Date:November 2, 1999

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Name:Indinavir sulfate
Intervention Type:Drug
Name:Amprenavir

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Glaxo Wellcome

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.